Back to search
Hereditary Breast and Ovarian Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hereditary Breast and Ovarian Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hereditary Breast and Ovarian Cancer trials you may qualify forPhase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
The aim of this study is to determine the frequency of the three most common BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) genetic mutations tha…
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimens…
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receiv…
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor…
The goal of this multi-center observational study is to learn about the effectiveness and safety of different prophylactic (preventive) surgical options in wome…
This study will evaluate women who are at increased genetic risk of developing ovarian cancer because they or a close relative have a mutation in the BRCA1 or B…
Despite relevant clinical and/or familial presentations suggesting a hereditary predisposition (early-onset, multiple primary tumors, familial aggregation), tar…
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. I…